Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SMMT

Summit Therapeutics Inc

Sep 19 • 04:00PM ET

23.16

Dollar change -1.40
Percentage change -5.70	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI XBI VXF IWO VB IBB SCHA VBR FYX

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.23	Insider Own	85.88%	Shs Outstand	701.66M	Perf Week	-15.51%
Market Cap	16.78B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	0.03%	Shs Float	102.27M	Perf Month	88.14%
Income	-161.73M	PEG	-	EPS next Q	-0.07	Inst Own	10.00%	Short Float	17.83%	Perf Quarter	196.92%
Sales	0.00M	P/S	-	EPS this Y	72.30%	Inst Trans	-29.20%	Short Ratio	4.16	Perf Half Y	504.70%
Book/sh	0.27	P/B	85.99	EPS next Y	-9.48%	ROA	-55.84%	Short Interest	18.23M	Perf Year	1131.91%
Cash/sh	0.45	P/C	51.49	EPS next 5Y	-	ROE	-102.79%	52W Range	1.64 - 33.89	Perf YTD	787.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-80.83%	52W High	-31.66%	Beta	-1.08
Dividend TTM	-	Quick Ratio	2.35	Sales past 5Y	-28.65%	Gross Margin	-	52W Low	1312.20%	ATR (14)	2.65
Dividend Ex-Date	-	Current Ratio	2.35	EPS Y/Y TTM	86.40%	Oper. Margin	0.00%	RSI (14)	60.82	Volatility	15.01% 12.37%
Employees	105	Debt/Eq	0.56	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	29.67
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-304.27%	Payout	-	Rel Volume	1.51	Prev Close	24.56
Sales Surprise	-	EPS Surprise	19.22%	Sales Q/Q	-	Earnings	Aug 06 BMO	Avg Volume	4.39M	Price	23.16
SMA20	28.88%	SMA50	73.32%	SMA200	244.47%	Trades		Volume	6,600,415	Change	-5.70%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy	$30 → $27
Feb-13-18	Initiated	BTIG Research	Buy	$33
Jan-04-18	Initiated	SunTrust	Buy	$24
Dec-01-17	Resumed	H.C. Wainwright	Buy	$16
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform	$26 → $29
Oct-05-16	Reiterated	Needham	Buy	$22 → $30
Sep-16-16	Initiated	H.C. Wainwright	Buy	$26
Mar-30-15	Initiated	Oppenheimer	Outperform	$28
Mar-30-15	Initiated	Needham	Buy	$22

Show Previous Ratings

Today 12:02PM	BioNTech Is More Than a Covid-19 Stock. Its Having a Great September. (Barrons.com) -5.70%
05:50AM	Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? (Motley Fool)
Sep-18-24 09:53AM	This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. (Motley Fool) -6.33%
Sep-17-24 04:09PM	How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery (Investor's Business Daily) -11.06%
04:24AM	Here's Why Everyone's Talking About Summit Therapeutics (Motley Fool)
06:30AM	Loading…
Sep-16-24 06:30AM	Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 (Business Wire) -7.67%
Sep-14-24 11:44AM	Is Summit Therapeutics Inc. (NASDAQ:SMMT) an Unstoppable Growth Stock To Buy Now? (Insider Monkey)
Sep-13-24 10:30AM	Why Summit Therapeutics Skyrocketed 123% This Week (Motley Fool) +16.49%
Sep-12-24 04:06PM	Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale (Investor's Business Daily) +20.75%
11:53AM	Why Summit Therapeutics Stock Is Soaring Again Today (Motley Fool)
06:30AM	Summit Therapeutics Raises $235 Million (Business Wire)
Sep-11-24 07:08PM	Summit Therapeutics Co-CEOs on what's next for lung cancer drug (CNBC TV)
Sep-10-24 04:27AM	Is Summit Therapeutics a Buy Now? (Motley Fool) +20.01%
Sep-09-24 04:11PM	Merck Dives After Summit Up 56% Sneaks In With Keytruda-Walloping Punch (Investor's Business Daily) +55.99%
02:01PM	Why Summit Therapeutics Rocketed Over 60% Today (Motley Fool)
01:55PM	Loading…
01:55PM	A Better Drug Than Mercks Blockbuster Keytruda? Not So Fast (The Wall Street Journal)
12:54PM	Top Stock Movers Now: Boeing, Palantir Technologies, Merck, and More (Investopedia)
12:13PM	Summits checkpoint inhibitor trumps Keytruda in lung cancer trial (Pharmaceutical Technology)
09:59AM	Merck stock falls on Summit cancer drug's trial results (Yahoo Finance Video)
09:54AM	Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial (Barrons.com)
09:50AM	Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today (Investopedia)
09:07AM	Merck Dives After Summit Therapeutics Sneaks In With Keytruda-Walloping Punch (Investor's Business Daily)
08:06AM	Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda (Investor's Business Daily)
08:02AM	Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half (Benzinga)
Sep-08-24 11:45AM	Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China (Business Wire)
07:38AM	Summit lung cancer drug shows striking benefit over Keytruda (BioPharma Dive)
Sep-06-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +55.99%
Aug-12-24 07:00AM	HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024 (Business Wire)
Aug-11-24 07:30PM	Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024 (PR Newswire)
Aug-09-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.27%
07:00AM	Loading…
Aug-06-24 07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 (Business Wire)
Jul-29-24 04:15PM	Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024 (Business Wire) -6.67%
Jul-25-24 08:00AM	Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab (Business Wire) +5.11%
Jul-03-24 04:15PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.62% +5.08%
Jun-27-24 04:15PM	Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors (Business Wire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-17-24 05:50AM	3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street (Motley Fool) -5.84%
Jun-12-24 09:14AM	Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why (Zacks) +9.42%
Jun-03-24 05:30AM	Summit Raises $200 Million; Also Expands License Territories for Ivonescimab (Business Wire)
Jun-01-24 08:00AM	Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA (Business Wire)
May-31-24 07:00PM	Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy (Business Wire) -20.47%
12:21PM	Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study (Benzinga)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
04:25AM	Summit reports data from Phase III NSCLC treatment trial (Clinical Trials Arena)
May-30-24 06:00PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +272.06%
04:50PM	Summit Shares Soar After Cancer Drug Tops Mercks Keytruda (Bloomberg)
03:22PM	Competitor to Merck's Keytruda Worries Some Investors (Barrons.com)
02:29PM	Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China (Business Wire)
May-28-24 12:13PM	Why Summit Therapeutics Stock Is Sinking Today (Motley Fool) -29.29%
May-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -21.76%
May-02-24 11:42AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript (Insider Monkey) -13.62%
03:15AM	Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ... (GuruFocus.com)
12:00AM	Q1 2024 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-24 11:55AM	SMMT Stock Earnings: Summit Therapeutics Reported Results for Q1 2024 (InvestorPlace) +19.59%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 (Business Wire)
Apr-24-24 04:30PM	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 (Business Wire)
Apr-11-24 04:30PM	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors (Business Wire) -9.06%
Apr-10-24 07:00AM	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum (Business Wire)
Apr-09-24 04:18PM	CORRECTED-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra named successor (Reuters)
04:05PM	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer (PR Newswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-29-24 05:43PM	Why Summit Therapeutics Stock Crushed the Market This Week (Motley Fool)
01:35PM	Hedge Fund and Insider Trading News: Cliff Asness, David Tepper, Ray Dalio, Mark Yusko, Baupost Group, Irenic Capital Management, Summit Therapeutics Inc (SMMT), Workday, Inc. (WDAY), and More (Insider Monkey)
Mar-22-24 07:00AM	Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024 (Business Wire) -5.07%
Mar-19-24 09:32AM	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.79%
Mar-14-24 07:00AM	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 (Business Wire) +5.32%
Mar-05-24 07:00AM	Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference (Business Wire) +13.17%
Feb-21-24 08:53AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.89%
01:56AM	Q4 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 08:31AM	Summit Therapeutics Inc (SMMT) Reports Comprehensive 2023 Financial Results and Clinical ... (GuruFocus.com) -26.23%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023 (Business Wire)
Feb-14-24 10:29AM	Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024 (Business Wire)
07:00AM	Summit Therapeutics to Host Fourth Quarter & Full Year 2023 (Business Wire)
Feb-07-24 07:00AM	Summit Therapeutics to Present at Oppenheimers 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-08-24 09:00AM	Summit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +16.47%
Jan-03-24 07:30AM	Summit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-08-23 12:27PM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 09:07AM	Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational Progress (GuruFocus.com) -12.16%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023 (Business Wire)
Nov-02-23 04:41PM	Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development (Business Wire)
08:00AM	Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023 (PR Newswire)
Oct-31-23 08:00AM	Ivonescimabs Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023 (Business Wire)
Oct-26-23 08:00AM	Summit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023 (Business Wire)
Oct-19-23 08:00AM	H. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development (Business Wire)
Oct-16-23 11:01PM	Insider Buying: COO Manmeet Soni Acquires 2,976,190 Shares of Summit Therapeutics Inc (GuruFocus.com) +15.43%
07:00AM	Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer (Business Wire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Aug-09-23 10:19PM	Q2 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +10.86% -8.25%
07:00AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023 (Business Wire)
Aug-02-23 08:00AM	Summit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023 (Business Wire) -6.70%
Jul-11-23 11:48AM	Summit Therapeutics Insiders Up US$558m On US$517m Investment (Simply Wall St.)
Jun-04-23 08:00AM	Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023 (Business Wire)
Jun-01-23 07:30AM	Ivonescimab Updated Data to be Featured at ASCO 2023 (Business Wire)
May-22-23 09:30AM	11 Stocks with Heavy Insider Buying in 2023 (Insider Monkey) -5.36%
May-18-23 09:46AM	After buying recently, Summit Therapeutics Inc. (NASDAQ:SMMT) insiders must be dismayed to see the company's market cap drop to US$1.2b (Simply Wall St.)
May-16-23 01:21PM	Why Shares of Summit Therapeutics Slumped on Tuesday (Motley Fool) -15.85%
11:44AM	Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 11:18PM	Q1 2023 Summit Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.20% -10.65%
12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey)
07:30AM	Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023 (Business Wire)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	54,321	201,874	24,923,800	Mar 27 08:28 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 26 '24	Buy	3.75	30,000	112,500	30,000	Mar 27 08:28 PM
Zanganeh Mahkam	Chief Executive Officer	Mar 27 '24	Buy	3.72	26,000	96,720	520,814	Mar 27 08:28 PM
Dhingra Ankur	Chief Financial Officer	Mar 26 '24	Buy	3.75	100,000	375,000	354,958	Mar 27 08:27 PM
Zanganeh Mahkam	Chief Executive Officer	Dec 12 '23	Buy	2.07	5,000	10,350	494,814	Dec 13 05:11 PM
Dhingra Ankur	Chief Financial Officer	Dec 13 '23	Buy	2.17	20,400	44,254	254,958	Dec 13 04:49 PM
Soni Manmeet Singh	Chief Operating Officer	Oct 13 '23	Buy	1.68	2,976,190	4,999,999	2,976,190	Oct 16 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience